$JAZZ · Jazz Pharmaceuticals plc
Jazz Pharmaceuticals filed its 10-Q for the quarter ended September 30, 2026. Total revenues grew 10.4% YoY to $1.243B, with product sales up 12% to $1.197B. The company swung to a GAAP net loss of $(483.4M) — or $(7.48) per diluted share — from a $251.4M profit a year ago, entirely due to a $754.2M acquired in-process research and development charge tied to the September 15, 2026 acquisition of Actio Biosciences. Excluding that charge, operating trends were favorable: SG&A dropped 23% and gross margin on product sales improved.
- Q3 net loss of $(483.4M) vs $251.4M profit a year ago, driven by a $754.2M acquired IPR&D charge for the Actio Biosciences acquisition.
- Total revenue rose 10.4% YoY to $1.243B; product sales grew 12% to $1.197B led by Xywav (+12%) and Zepzelca (+32%).
- SG&A fell 23% YoY to $407.9M, while R&D rose 7% to $211.9M.
- Nine-month operating income swung to $171.4M from a $(684.8M) loss, aided by a $122.8M gain on sale of a priority review voucher.
- Weighted-average diluted shares rose to 64.7M from 61.6M, reflecting exchangeable note dilution and share-based compensation.
Extended-hours trading shows a muted +0.27% reaction to $215.01, suggesting the large IPR&D-driven GAAP loss was anticipated or discounted. The $13.92B market cap implies the market is looking through the non-cash charge to underlying revenue growth.
A $754M one-time charge masks strong 10%+ revenue growth across Jazz's core franchises, but the Actio bet and mounting ANDA challenges for Epidiolex and Zepzelca create a binary risk-reward setup.
Jazz's heavy reliance on acquired IPR&D charges mirrors mid-cap biopharma peers using M&A to replenish pipelines. The 10%+ revenue growth from Xywav and Zepzelca offsets the oxybate franchise's gradual erosion from authorized generics and Avadel's Lumryz competition.
The $754.2M acquired IPR&D charge for Actio represents a binary bet on early-stage pipeline assets; if Actio programs fail, the entire charge becomes a permanent impairment. ANDA filers for both Epidiolex and Zepzelca pose generic-launch risk that could erode two key revenue franchises.